Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun 2:13:939789.
doi: 10.3389/fimmu.2022.939789. eCollection 2022.

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms

Janin Chandra  1 , Morten Hansen  2 , Nathalie Labarriere  3   4 , Ilaria Marigo  5   6 , Fernando Souza-Fonseca-Guimaraes  1 , Lazar Vujanovic  7   8 , Yoshinobu Koguchi  9 , Nicolas Jacquelot  10
Affiliations
Editorial

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms

Janin Chandra et al. Front Immunol. .
No abstract available

Keywords: adoptive T cell therapy,; cancer; immune checkpoint blockers; immunotherapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

YK receives funding from Tesaro, a GSK company, Bristol-Myers Squibb, and Shimadzu Corporation. LV is a co-inventor of a methodology licensed to INmune Bio, Inc. where a selective inhibitor of soluble TNF can be used to prevent or treat malignancies. MH receives funding from ImmuniTrack A/S as part of a consultancy agreement. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Cancer Immunotherapies: From Efficacy to Resistance Mechanisms

References

    1. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. . Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol (2019) 20:1083–97. doi: 10.1016/S1470-2045(19)30274-8 - DOI - PubMed
    1. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell (2021) 184:5309–37. doi: 10.1016/j.cell.2021.09.020 - DOI - PMC - PubMed

Publication types